Post-earnings recap
Reported
Tue, Mar 12, 2019
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Denali Therapeutics' earnings report showed a solid EPS figure, although revenue details were not disclosed. The stock reacted positively, rising 1.79%, likely due to the company's progress in its drug development efforts. Investors may be encouraged by management's optimistic tone regarding future advancements.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.79 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management expressed satisfaction with the company's progress and emphasized their commitment to advancing their drug development pipeline.
We are pleased with our progress in the quarter.
Our focus remains on advancing our pipeline.